Core Points - Sienna Resources Inc. has announced a non-brokered private placement to raise up to $3,000,000 at a price of $0.12 per unit, with each unit consisting of one common share and one transferable share purchase warrant priced at $0.17 for a period of 60 months [1][2][3] - The net proceeds from the financing will be allocated towards general working capital and evaluating existing projects, including drill programs for gold and lithium [2][3] - The company has approximately 25 million shares outstanding, with a pre-raise valuation of under $3 million, indicating an attractive opportunity for investors [3] Financial Details - The financing aims to raise up to $3,000,000 at a unit price of $0.12, with each unit including a share purchase warrant [1][2] - The share purchase warrant allows for the purchase of common shares at $0.17 for 60 months from the closing date [1] - The financing is subject to necessary approvals from the TSX Venture Exchange and other regulatory bodies [2] Management Commentary - Jason Gigliotti, President of Sienna Resources Inc., emphasized that the financing will enable the company to engage in multiple programs and maintain a robust marketing budget, with expectations of being very active in 2025-26 [3]

Core Points - Sienna Resources Inc. has successfully closed a non-brokered private placement under the Listed Issuer Financing Exemption, raising gross proceeds of $499,957.50 by selling 4,761,500 units at a price of $0.105 per unit [1] - Each unit consists of one common share and one transferable share purchase warrant, which can be exercised at a price of $0.14 for a period of 60 months [1] - The net proceeds will be allocated for general working capital and to fund exploration and development activities on existing projects [2] Financial Details - The company paid a cash finder's fee of $10,080.53 and issued 96,005 non-transferable finder's warrants, each exercisable at $0.14 for 24 months [2] - The financing is expected to provide the company with the necessary resources to initiate fieldwork and exploration activities during the summer [4] Project Focus - Sienna's immediate priority is the Stonesthrow Gold Project in Saskatchewan, covering approximately 31,718 contiguous acres [3] - The company is also evaluating its Case Lake lithium project in Ontario and its lithium assets in Nevada [3] Management Commentary - Jason Gigliotti, President of Sienna, emphasized the potential of the Stonesthrow Gold Project due to its strategic location and scale, indicating a phase of growth focused on active exploration and value creation [4]

Core Viewpoint - Sienna Resources Inc. is conducting a non-brokered private placement to raise up to $500,000 at a price of $0.105 per unit, with each unit consisting of one common share and one transferable share purchase warrant priced at $0.14 for a period of 60 months from the closing date [1][2]. Group 1 - The offering is expected to close around June 18, 2025, and is subject to necessary approvals from the TSX Venture Exchange and other regulatory bodies [2]. - Proceeds from the placement will be allocated to general working capital and evaluation of existing projects [2]. - The company aims to commence operations on at least one project this summer, focusing on the "Stonesthrow Gold Project," which spans approximately 31,718 contiguous acres [3]. Group 2 - The company is also assessing its Case Lake Project and Nevada lithium projects, indicating a diversified approach to resource exploration [3]. - The offering will be available to Canadian residents, excluding Quebec, under the Listed Issuer Financing Exemption, allowing for immediate trading of the securities without a hold period [3]. - The securities issued in the offering have not been registered under the United States Securities Act of 1933 and cannot be sold in the U.S. without proper registration or exemption [4].

Product Developments - Sientra received FDA 510k clearance for the AlloX2 Pro Tissue Expander on June 8, 2023, which is the first tissue expander cleared for MRI exposure in the U.S.[140] - The company announced the commercial launch of the Viality Fat Transfer System on March 1, 2023, with interim clinical study results showing 80% fat retention at 3, 6, and 12 months[143] - Sientra entered into a partnership with Elutia Inc. on March 22, 2023, to expand the distribution of SimpliDerm ADM for reconstruction surgery, beginning commercial sales in Q2 2023[142] Financial Performance - Net sales decreased by approximately $3.0 million, or 13.4%, to $19.5 million for the three months ended September 30, 2023, compared to $22.6 million for the same period in 2022[166] - Gross profit for the three months ended September 30, 2023, was $10.0 million, down from $12.8 million in 2022, reflecting a gross margin decrease from 56.6% to 51.3%[168] - Total operating expenses decreased by approximately $5.9 million, or 23.3%, to $19.4 million for the three months ended September 30, 2023, compared to $25.3 million for the same period in 2022[175] - The company incurred a net loss of $14.8 million for the three months ended September 30, 2023, compared to a net loss of $14.9 million for the same period in 2022[165] - For the nine months ended September 30, 2023, net sales were $65.2 million, a slight decrease of $0.3 million, or 0.4%, from $65.5 million in 2022[176] - Cost of goods sold increased by approximately $3.3 million, or 12.3%, to $30.4 million for the nine months ended September 30, 2023, compared to $27.1 million in 2022[177] - The company reported a net loss of $37.1 million for the nine months ended September 30, 2023, down from a net loss of $51.3 million in 2022[175] Cash Flow and Liquidity - Cash and cash equivalents as of September 30, 2023, were $15.0 million, with the company using $11.0 million of cash from continuing operations during the nine months[184] - The company is evaluating various cost-saving measures to reduce operating expenses and cash outflows, while also seeking to generate significant increases in net sales[185] - As of September 30, 2023, the company did not meet the required minimum revenue financial covenant under the Restated Agreement, leading to potential acceleration of debt repayment[189] - Net cash used in investing activities decreased to $1.1 million for the nine months ended September 30, 2023, from $1.9 million in the same period of 2022[195] - Net cash provided by financing activities was $0.2 million during the nine months ended September 30, 2023, down from $2.7 million in the prior year, primarily due to the absence of borrowings under the Term Loan and Revolving Loan[196] - The company’s liquidity position and capital requirements are influenced by factors such as manufacturing capacity, sales generation, and costs associated with product development and regulatory compliance[198] - The company may need to sell additional equity or debt securities if cash generated from operations is insufficient to meet working capital and capital expenditure requirements[199] Market Conditions and Business Environment - The COVID-19 pandemic has had a lingering effect on Sientra's business, with uncertainty regarding the return of aesthetic procedures to pre-pandemic levels[144] - Sientra's net sales consist primarily of silicone gel breast implants, tissue expanders, and the Viality fat transfer system, with revenue recognition based on specific return policies[147] - The company expects fluctuations in net sales due to seasonality in breast augmentation procedures and macroeconomic conditions[148] - Sientra's overall gross margin is expected to fluctuate based on unit sales, manufacturing costs, and product mix[152] - Research and development expenses are anticipated to vary with new product development and clinical studies[154] - The company has made appropriate estimates regarding the impact of macroeconomic conditions on its financial results, which may change as new information becomes available[146] Regulatory and Compliance - There are currently no off-balance sheet arrangements as defined under SEC rules[200] - The company has not disclosed any quantitative and qualitative disclosures about market risk as it is classified as a smaller reporting company[202]

Financial Performance - Net sales increased by approximately $1.6 million, or 7.5%, to $23.1 million for the three months ended June 30, 2023, compared to $21.5 million for the same period in 2022, driven by increased domestic sales of gel implants and revenue from the new Viality product [147]. - Gross profit for the three months ended June 30, 2023, was $12.6 million, a slight decrease from $12.7 million in the same period of 2022 [146]. - Net sales increased approximately $2.8 million, or 6.5%, to $45.7 million for the six months ended June 30, 2023, compared to $42.9 million for the same period in 2022, driven by increased domestic sales of gel implants and revenue from the new product Viality [156]. - Gross margins for the six months ended June 30, 2023, were approximately 54.2%, down from 59.6% in 2022, primarily due to amortization of Viality-related manufacturing know-how intangible assets [158]. Operating Expenses - Cost of goods sold rose by approximately $1.7 million, or 19.9%, to $10.5 million for the three months ended June 30, 2023, primarily due to amortization of Viality-related manufacturing know-how and increased warranty provisions [148]. - Total operating expenses decreased to $19.7 million for the three months ended June 30, 2023, from $28.7 million in the same period of 2022, reflecting reduced sales and marketing, research and development, and general and administrative expenses [146]. - Total operating expenses decreased approximately $15.2 million, or 26.4%, to $42.4 million for the six months ended June 30, 2023, compared to $57.6 million for the same period in 2022 [155]. - Research and Development expenses decreased approximately $1.0 million, or 16.5%, to $5.1 million for the six months ended June 30, 2023, due to reduced costs related to regulatory activities and product development [160]. - General and Administrative expenses decreased approximately $5.1 million, or 22.8%, to $17.2 million for the six months ended June 30, 2023, primarily due to reductions in consulting and insurance fees [161]. Losses and Cash Flow - Loss from operations improved to $(7.1) million for the three months ended June 30, 2023, compared to $(15.9) million for the same period in 2022 [146]. - The company incurred net losses of $22.4 million and used $7.4 million of cash from continuing operations during the six months ended June 30, 2023 [165]. - Cash used in operating activities was $6.8 million for the six months ended June 30, 2023, a decrease from $30.8 million in the same period of 2022, reflecting improved working capital [170]. - As of June 30, 2023, the company had cash and cash equivalents of $18.6 million, raising substantial doubt about its ability to continue as a going concern for at least one year [165]. Strategic Developments - The company received FDA 510k clearance for the AlloX2 Pro Tissue Expander on June 8, 2023, which is now MRI-conditional, enhancing its market offering [122]. - The Portfinder technology, an electronic device for locating ports in tissue expanders, received FDA 510k clearance on May 17, 2023, improving usability for clinicians [123]. - The company entered into a partnership with Aziyo Biologics on March 22, 2023, to expand the distribution of SimpliDerm ADM products in the U.S. [124]. - Commercial shipping of the Viality fat transfer system began on March 1, 2023, following its acquisition in December 2021 [125]. - The company anticipates fluctuations in net sales due to seasonal trends in aesthetic procedures and ongoing macroeconomic conditions [131]. - The company is evaluating various cost-saving measures to reduce operating expenses and cash outflows, while also seeking to generate significant increases in net sales [166]. - The company plans to seek additional funding alternatives to improve liquidity, which may include raising equity or debt capital [166].

Financial Performance - Net sales increased by approximately $1.2 million, or 5.4%, to $22.6 million for the three months ended March 31, 2023, compared to $21.4 million for the same period in 2022[143]. - Cost of goods sold increased by approximately $1.9 million, or 21.7%, to $10.4 million for the three months ended March 31, 2023, compared to $8.6 million for the same period in 2022[144]. - Gross margins decreased to approximately 53.9% for the three months ended March 31, 2023, down from 60.0% for the same period in 2022[145]. - The company incurred net losses of $12.9 million during the three months ended March 31, 2023, and used $6.7 million of cash from continuing operations[151]. - Net cash used in operating activities was $6.3 million during the three months ended March 31, 2023, a decrease from $17.9 million during the same period in 2022[157]. - Net cash used in investing activities was $0.6 million during the three months ended March 31, 2023, compared to $0.2 million in the same period in 2022[158]. - Net cash provided by financing activities was $0.2 million during the three months ended March 31, 2023, a decrease from $5.3 million during the same period in 2022[159]. Expenses - Sales and marketing expenses decreased by approximately $5.4 million, or 34.9%, to $10.2 million for the three months ended March 31, 2023, compared to $15.6 million for the same period in 2022[146]. - Research and development expenses decreased by approximately $0.4 million, or 13.9%, to $2.7 million for the three months ended March 31, 2023, compared to $3.1 million for the same period in 2022[147]. - General and Administrative (G&A) expenses decreased by approximately $0.4 million, or 3.5%, to $9.9 million for the three months ended March 31, 2023, compared to $10.2 million for the same period in 2022[148]. Cash Position and Financing - As of March 31, 2023, the company had cash and cash equivalents of $19.4 million, raising substantial doubt about its ability to continue as a going concern for at least one year[151]. - The company is evaluating various cost-saving measures to reduce operating expenses and cash outflows, while also seeking to generate significant increases in net sales[152]. - The company anticipates that losses will continue in the near term, necessitating potential additional equity or debt financing[152]. - The company issued and sold 1,778,500 shares of common stock, raising approximately $14.0 million in net proceeds on October 25, 2022[154]. Business Developments - The Company launched the Viality fat transfer system commercially on March 1, 2023, following its acquisition in December 2021[122]. - The Company entered into a partnership with Aziyo Biologics to expand the distribution of the SimpliDerm product line for reconstruction surgery[121]. - The Company has one operating segment named Plastic Surgery, focusing on breast implants, tissue expanders, fat transfer, and scar management[120]. Market Conditions - The Company expects net sales to fluctuate quarterly due to seasonality and macroeconomic conditions[127]. - The company continues to face risks from global economic conditions, including inflation and consumer confidence[124].

Financial Performance - Net sales increased by $9.9 million, or 12.2%, to $90.6 million for the year ended December 31, 2022, compared to $80.7 million in 2021, driven by higher domestic and international sales of gel implants and expanders [409]. - The company incurred a net loss of $73.3 million for the year ended December 31, 2022, compared to a net loss of $62.5 million in 2021 [408]. - Cash used in operating activities was $34.9 million for the year ended December 31, 2022, a decrease from $44.5 million in 2021, primarily due to improved working capital [424]. - As of December 31, 2022, the company had cash and cash equivalents of $26.1 million, raising substantial doubt about its ability to continue as a going concern for at least one year [419]. Debt and Financing - The company reported a total debt reduction of approximately $10 million, bringing the total debt load to $73 million, with maturity dates extended to March 2026 and beyond [348]. - The company completed an equity financing on October 25, 2022, raising approximately $14.0 million from the sale of 1,778,500 shares of common stock at an offering price of $3.80 per share [352]. - The company issued 1,778,500 shares of common stock and raised approximately $14.0 million in net proceeds on October 25, 2022 [421]. Product Development and Market Expansion - The company received approval from the UAE Ministry of Health and Prevention to market its silicone gel breast implants on December 13, 2022, and began commercialization through its distribution partner [353]. - The company launched the Viality Fat Transfer System on March 1, 2023, following its acquisition from AuraGen Aesthetics LLC [346]. - The company has expanded its market presence internationally, with approvals in Japan, Saudi Arabia, Canada, and the UAE since 2020 [344]. - The company’s breast implants are offered in approximately 350 variations, incorporating technologies that differentiate them from competitors, including High-Strength Cohesive silicone gel [364]. - The company’s clinical trial data demonstrated comparable or better rupture rates, capsular contracture rates, and reoperation rates compared to competitors [365]. - The company’s breast implants were approved by the FDA in 2012, based on a long-term clinical trial involving 1,788 women across 36 investigational sites [365]. Revenue and Cost Management - The company’s revenue recognition for breast implants and tissue expanders is net of sales discounts and estimated returns, with a standard six-month return window for customers [370]. - The overall gross margin is anticipated to fluctuate due to factors such as unit sales quantity, manufacturing price increases, and warranty costs [374]. - Gross margin decreased to 45.9% in 2022 from 54.9% in 2021, mainly due to increased reserves for excess inventory; adjusted gross margin was 52.0% excluding inventory reserve adjustments [411]. - Cost of goods sold rose by $12.6 million, or 34.7%, to $49.0 million for the year ended December 31, 2022, primarily due to increased sales activity and higher reserves for warranty and excess inventory [410]. Expenses and Liabilities - Sales and marketing expenses increased by $6.6 million, or 13.6%, to $55.0 million for the year ended December 31, 2022, attributed to higher payroll, travel, and marketing initiatives [412]. - Research and development expenses rose by $3.6 million, or 34.5%, to $14.1 million for the year ended December 31, 2022, due to increased product development and regulatory expenses [413]. - General and administrative expenses increased by $9.8 million, or 30.7%, to $41.5 million for the year ended December 31, 2022, driven by higher legal and consulting fees [414]. - The company held total warranty liabilities of $8.8 million as of December 31, 2022, compared to $2.5 million in 2021 [393]. - As of December 31, 2022, the liability for unsatisfied performance obligations under the service warranty was $3.508 million, with a long-term portion of $2.646 million [388]. - The sales return liability increased to $15.773 million as of December 31, 2022, from $13.399 million in 2021, reflecting changes in estimated sales returns [390]. Research and Development - Research and development expenses are expected to vary based on the initiation of different development projects, including improvements to existing products and new product acquisitions [376]. Warranty and Customer Support - The company introduced the Platinum20 warranty program in May 2018, which includes financial assistance for revision surgeries and no-charge contralateral replacement implants [387]. - The company expects sales and marketing expenses to fluctuate due to headcount changes and the timing of marketing programs [375]. Acquisitions - Acquisitions are evaluated to determine if they should be accounted for as business combinations or asset acquisitions based on the concentration of fair value in identifiable assets [399].

Financial Performance - Net sales increased by approximately $3.0 million, or 15.0%, to $22.6 million for the three months ended September 30, 2022, compared to $19.6 million for the same period in 2021[148] - Net sales increased by approximately $7.4 million, or 12.8%, to $65.5 million for the nine months ended September 30, 2022, compared to $58.0 million for the same period in 2021[159] - Loss from operations was $12.6 million for the three months ended September 30, 2022, compared to a loss of $11.7 million for the same period in 2021[147] - Net loss for the three months ended September 30, 2022, was $14.98 million, compared to a net loss of $28.41 million for the same period in 2021[147] - Net loss for the nine months ended September 30, 2022, was $51.3 million, compared to a net loss of $46.4 million for the same period in 2021[158] Cost and Expenses - Cost of goods sold rose by approximately $0.8 million, or 8.5%, to $9.8 million for the three months ended September 30, 2022, compared to $9.0 million for the same period in 2021[149] - Cost of goods sold increased by approximately $1.1 million, or 4.2%, to $27.1 million for the nine months ended September 30, 2022, compared to $26.0 million for the same period in 2021[160] - Sales and marketing expenses increased by approximately $0.2 million, or 2.0%, to $12.3 million for the three months ended September 30, 2022, compared to $12.1 million for the same period in 2021[151] - Sales and marketing expenses rose by approximately $7.2 million, or 20.9%, to $41.5 million for the nine months ended September 30, 2022, compared to $34.3 million for the same period in 2021[163] - Research and development expenses surged by approximately $1.4 million, or 57.2%, to $3.7 million for the three months ended September 30, 2022, compared to $2.4 million for the same period in 2021[152] - Research and development expenses increased by approximately $2.9 million, or 41.1%, to $9.8 million for the nine months ended September 30, 2022, compared to $7.0 million for the same period in 2021[164] - General and administrative expenses rose by approximately $1.5 million, or 18.6%, to $9.3 million for the three months ended September 30, 2022, compared to $7.9 million for the same period in 2021[153] - General and administrative expenses increased by approximately $8.3 million, or 35.5%, to $31.6 million for the nine months ended September 30, 2022, compared to $23.3 million for the same period in 2021[165] Profitability Metrics - Gross margin improved to approximately 56.6% for the three months ended September 30, 2022, up from 54.0% for the same period in 2021[150] - Gross margin improved to 58.6% for the nine months ended September 30, 2022, up from 55.2% for the same period in 2021[161] Cash Flow and Financing - Cash used in operating activities was $33.5 million for the nine months ended September 30, 2022, compared to $28.6 million for the same period in 2021[175] - The company had cash and cash equivalents of $19.0 million as of September 30, 2022[169] - The company completed a public offering on October 25, 2022, raising approximately $13.7 million in net proceeds[171] Interest and Taxes - Interest income was $41, while interest expense was $2.36 million for the three months ended September 30, 2022[147] - There was no income tax expense for the three months ended September 30, 2022, and 2021[155]

Financial Performance - Net sales increased by $1.4 million, or 7.0%, to $21.5 million for the three months ended June 30, 2022, compared to $20.1 million for the same period in 2021[121] - The company reported a loss from operations of $15.9 million for the three months ended June 30, 2022, compared to a loss of $9.2 million for the same period in 2021[120] - The company experienced a net loss of $18.3 million for the three months ended June 30, 2022, compared to a net loss of $20.1 million for the same period in 2021[120] - Net sales increased by $4.5 million, or 11.7%, to $42.9 million for the six months ended June 30, 2022, compared to $38.4 million for the same period in 2021[131] - The company incurred a net loss of $36.3 million for the six months ended June 30, 2022, compared to a net loss of $74.8 million for the same period in 2021[130] Cost and Expense Management - Gross margin improved to 59.2% for the three months ended June 30, 2022, up from 56.0% in the same period of 2021, primarily due to a decrease in unit costs of gel implants[122] - Total operating expenses increased to $28.7 million for the three months ended June 30, 2022, up from $20.4 million in the same period of 2021[120] - Sales and marketing expenses rose by $3.2 million, or 30.4%, to $13.7 million for the three months ended June 30, 2022, driven by increased payroll and marketing initiatives[123] - Research and development expenses increased by $0.6 million, or 23.3%, to $3.0 million for the three months ended June 30, 2022, mainly due to higher clinical and regulatory costs[124] - General and administrative expenses surged by $4.5 million, or 59.8%, to $12.1 million for the three months ended June 30, 2022, attributed to higher payroll and legal settlement fees[125] - Gross margin improved to 59.6% for the six months ended June 30, 2022, up from 55.8% in 2021, primarily due to a decrease in unit costs of gel implants[132] - Sales and marketing expenses rose by $7.0 million, or 31.2%, to $29.3 million for the six months ended June 30, 2022, driven by increased payroll and marketing initiatives[133] - Research and development expenses increased by $1.5 million, or 32.8%, to $6.1 million for the six months ended June 30, 2022, due to higher clinical and regulatory costs[134] - General and administrative expenses grew by $6.8 million, or 44.1%, to $22.3 million for the six months ended June 30, 2022, mainly from increased payroll and legal fees[135] Cash Flow and Liquidity - Cash used in operating activities was $30.8 million for the six months ended June 30, 2022, compared to $14.8 million for the same period in 2021[144] - As of June 30, 2022, the company had cash and cash equivalents of $25.0 million, with the ability to receive an additional $14.0 million on a term loan[139] - The company is evaluating various funding alternatives to improve liquidity, including potential capital raises through equity securities and debt financing[140] Business Developments - The company received approval from Health Canada on March 23, 2022, to begin commercialization of its silicone gel breast implants in Canada[103] - The sales organization consisted of 76 employees as of June 30, 2022, unchanged from the previous year[121] - Loss from discontinued operations decreased by $1.5 million for the three months ended June 30, 2022, due to the sale of the miraDry business[128]

Financial Performance - Net sales increased by $3.1 million, or 16.9%, to $21.4 million for the three months ended March 31, 2022, compared to $18.3 million for the same period in 2021[119]. - Gross margin improved to 60.0% for the three months ended March 31, 2022, up from 55.4% in the same period of 2021, primarily due to a decrease in unit costs of gel implants[122]. - Cost of goods sold increased by $0.4 million, or 4.8%, to $8.6 million for the three months ended March 31, 2022, compared to $8.2 million for the same period in 2021[121]. Operating Expenses - Sales and marketing expenses rose by $3.8 million, or 31.9%, to $15.6 million for the three months ended March 31, 2022, compared to $11.8 million for the same period in 2021[124]. - Research and development expenses increased by $0.9 million, or 43.2%, to $3.1 million for the three months ended March 31, 2022, compared to $2.2 million for the same period in 2021[125]. - General and administrative expenses increased by $2.3 million, or 29.0%, to $10.2 million for the three months ended March 31, 2022, compared to $7.9 million for the same period in 2021[126]. Cash Flow - Net cash used in operating activities was $17.9 million for the three months ended March 31, 2022, compared to $12.8 million for the same period in 2021, primarily due to increases in accounts receivable and inventory[135]. - Net cash used in investing activities was $0.2 million for the three months ended March 31, 2022, a decrease from $1.3 million in the same period in 2021, due to reduced property and equipment purchases[136]. - Net cash provided by financing activities was $5.3 million for the three months ended March 31, 2022, down from $39.4 million in the same period in 2021, primarily due to a decrease in proceeds from the issuance of common stock[138]. - As of March 31, 2022, the company had $38.9 million in cash and cash equivalents, with historical cash outflows primarily associated with research and development activities[131]. Business Operations - The company has one operating segment in continuing operations named Plastic Surgery, focusing on breast implants, tissue expanders, and scar management products[99]. - As of March 31, 2022, the sales organization consisted of 76 employees, an increase from 66 employees in the same period of 2021[120]. - The company received approval from Health Canada on March 23, 2022, to begin commercialization of its smooth round HSC and HSC+ silicone gel breast implants in Canada[102]. Challenges and Future Outlook - The ongoing impact of the COVID-19 pandemic continues to affect the company's revenues, with restrictions on non-emergency procedures leading to significant revenue harm since the second quarter of 2020[103]. - The company anticipates that operating expenses will remain consistent and will need to generate significant net sales to achieve profitability[130]. - The company may need to raise additional debt or equity capital to fund ongoing operations, as cash generated from operations may be insufficient[141]. - The company has incurred significant net operating losses since inception and expects these losses to continue in the near term[130]. - The liquidity position and capital requirements are subject to various factors, including the ability to meet customer requirements and costs associated with regulatory compliance[140]. Other Financial Information - Other income (expense), net decreased due to a change in the fair value of the derivative liability, which did not reoccur in the current period[127]. - Loss from discontinued operations increased by $2.0 million due to the sale of the miraDry business[129].